Fundz
Back to SEC Filings
10-QMEDIUM RiskDETERIORATING

VITASPRING BIOMEDICAL CO. LTD.

Filed: Jan 30, 2026 CIK: 0001697884
View original filing on SEC.gov

AI Executive Summary

AI-powered analysis of 10-Q filing content

VITASPRING BIOMEDICAL is in severe financial distress with zero revenue for nine months, negative $3.2M stockholders' equity, and critically low cash of $2,636. The company has massive related-party debt of $2.4M and accumulated losses of $4.3M, indicating potential going concern issues.

Red Flags Detected (7)

Zero revenue for entire nine months of 2023 vs $1.49M in prior year

Cash depleted from $29,656 to $2,636 (91% decline)

Negative stockholders' equity of $3.2M

4 more red flags detected

Key Takeaways

Company appears to have no active business operations generating revenue

Immediate liquidity crisis with insufficient cash to sustain operations

2 more takeaways

Filing Overview

Form TypeQuarterly Report (10-Q)
Filing DateJan 30, 2026
Risk LevelMEDIUM
TrendDETERIORATING
AI Confidence95%
Red Flags7

What This Means

Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.

Quarterly Report: Interim filing with unaudited financial data for the quarter.

View Full Filing on SEC.govBrowse More Filings